Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

The therapeutic use of single-chain antibodies (VHHs) is limited by their short half-life in the circulation. Here the authors engineer mouse and human red blood cells to express VHHs against botulinum neurotoxin A (BoNT/A) on their surface and show that an infusion of these cells into mice confers...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nai-Jia Huang, Novalia Pishesha, Jean Mukherjee, Sicai Zhang, Rhogerry Deshycka, Valentino Sudaryo, Min Dong, Charles B. Shoemaker, Harvey F. Lodish
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/cc5b7658df0d48e1aa16746d22081aea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc5b7658df0d48e1aa16746d22081aea
record_format	dspace
spelling	oai:doaj.org-article:cc5b7658df0d48e1aa16746d22081aea2021-12-02T14:41:09ZGenetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin10.1038/s41467-017-00448-02041-1723https://doaj.org/article/cc5b7658df0d48e1aa16746d22081aea2017-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-017-00448-0https://doaj.org/toc/2041-1723The therapeutic use of single-chain antibodies (VHHs) is limited by their short half-life in the circulation. Here the authors engineer mouse and human red blood cells to express VHHs against botulinum neurotoxin A (BoNT/A) on their surface and show that an infusion of these cells into mice confers long lasting protection against a high dose of BoNT/A.Nai-Jia HuangNovalia PisheshaJean MukherjeeSicai ZhangRhogerry DeshyckaValentino SudaryoMin DongCharles B. ShoemakerHarvey F. LodishNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-13 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Nai-Jia Huang Novalia Pishesha Jean Mukherjee Sicai Zhang Rhogerry Deshycka Valentino Sudaryo Min Dong Charles B. Shoemaker Harvey F. Lodish Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
description	The therapeutic use of single-chain antibodies (VHHs) is limited by their short half-life in the circulation. Here the authors engineer mouse and human red blood cells to express VHHs against botulinum neurotoxin A (BoNT/A) on their surface and show that an infusion of these cells into mice confers long lasting protection against a high dose of BoNT/A.
format	article
author	Nai-Jia Huang Novalia Pishesha Jean Mukherjee Sicai Zhang Rhogerry Deshycka Valentino Sudaryo Min Dong Charles B. Shoemaker Harvey F. Lodish
author_facet	Nai-Jia Huang Novalia Pishesha Jean Mukherjee Sicai Zhang Rhogerry Deshycka Valentino Sudaryo Min Dong Charles B. Shoemaker Harvey F. Lodish
author_sort	Nai-Jia Huang
title	Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
title_short	Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
title_full	Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
title_fullStr	Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
title_full_unstemmed	Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
title_sort	genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/cc5b7658df0d48e1aa16746d22081aea
work_keys_str_mv	AT naijiahuang geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT novaliapishesha geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT jeanmukherjee geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT sicaizhang geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT rhogerrydeshycka geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT valentinosudaryo geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT mindong geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT charlesbshoemaker geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin AT harveyflodish geneticallyengineeredredcellsexpressingsingledomaincamelidantibodiesconferlongtermprotectionagainstbotulinumneurotoxin
_version_	1718390020942856192

Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin

Ejemplares similares